Prediction of Relapse and Glucocorticoid Dependence in Eosinophilic Granulomatosis with Polyangiitis: Findings from a Large European Cohort.

Date publication

février 2026

Journal

Arthritis & rheumatology (Hoboken, N.J.)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BONNOTTE Bernard

Tous les auteurs :
Papo M, Martinot P, Sinico RA, Silvestre-Teixeira V, Venhoff N, Urban ML, Iudici M, Mahrhold J, Locatelli F, Cassone G, Schiavon F, Seeliger B, Neumann T, Feder C, Groh M, Marvisi C, Samson M, Barba T, Jayne D, Troilo A, Thiel J, Hellmich B, Monti S, Montecucco C, Salvarani C, Kahn JE, Bonnotte B, Durel CA, Puéchal X, Mouthon L, Guillevin L, Emmi G, Vaglio A, Porcher R, Terrier B,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41656627

Résumé

Eosinophilic granulomatosis with polyangiitis (EGPA) is a small vessel vasculitis characterized by eosinophilia, asthma, and ear, nose, throat (ENT) involvement. Although glucocorticoids (GCs) are effective in controlling symptoms, relapses and GC dependence are common. The aim of this study was to develop predictive models for vasculitis relapse and GC-dependent asthma and/or ENT symptoms.

Référence

Arthritis Rheumatol. 2026 02 8;: